235 related articles for article (PubMed ID: 27498118)
1. Differentiating the Causes of Spontaneous Rib Fracture After Breast Cancer.
Harris SR
Clin Breast Cancer; 2016 Dec; 16(6):431-436. PubMed ID: 27498118
[TBL] [Abstract][Full Text] [Related]
2. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
4. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
6. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer and osteoporosis.
Cheung AM; Heisey R; Srighanthan J
Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):532-8. PubMed ID: 24468755
[TBL] [Abstract][Full Text] [Related]
8. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Rozenberg S; Carly B; Liebens F; Antoine C
Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
[TBL] [Abstract][Full Text] [Related]
9. [Bisphosphonate treatment against breast cancer with bone metastases].
Kohno N
Nihon Rinsho; 2007 Jun; 65 Suppl 6():575-81. PubMed ID: 17682213
[No Abstract] [Full Text] [Related]
10. Osteoporosis management in patients with breast cancer: EMAS position statement.
Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic approaches for protecting bone health in patients with breast cancer.
Lüftner D; Niepel D; Steger GG
Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
[TBL] [Abstract][Full Text] [Related]
12. [Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
Xiu Bing-He ;
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):876-9. PubMed ID: 24447490
[No Abstract] [Full Text] [Related]
13. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
Chukir T; Liu Y; Farooki A
Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
[TBL] [Abstract][Full Text] [Related]
14. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Tang SC
Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
[TBL] [Abstract][Full Text] [Related]
15. Managing the risk of osteoporosis in women with a history of early breast cancer.
Ravdin PM
Oncology (Williston Park); 2004 Oct; 18(11):1385-90, 1393; discussion 1394. PubMed ID: 15609468
[TBL] [Abstract][Full Text] [Related]
16. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Bouvard B; Chatelais J; Soulié P; Hoppé E; Saulnier P; Capitain O; Mege M; Mesgouez-Nebout N; Jadaud E; Abadie-Lacourtoisie S; Campone M; Legrand E
Eur J Cancer; 2018 Sep; 101():87-94. PubMed ID: 30036740
[TBL] [Abstract][Full Text] [Related]
17. A 66-year-old woman with spontaneous rib fracture.
Harris SR
CMAJ; 2015 Sep; 187(13):988-989. PubMed ID: 25733732
[No Abstract] [Full Text] [Related]
18. Severe low turnover osteoporosis.
Pietrogrande L
Aging Clin Exp Res; 2007 Aug; 19(4 Suppl):26-9. PubMed ID: 18182889
[TBL] [Abstract][Full Text] [Related]
19. Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors.
Rachner TD; Göbel A; Jaschke NP; Hofbauer LC
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32674135
[TBL] [Abstract][Full Text] [Related]
20. [Effect of aromatase inhibitors on bone metabolism].
Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
